Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).
| Image |  |
|---|---|
| Description | scientific article published on 7 July 2015 |
| Author/s |
author: Raphael Gottardo |
| Publication date | July 7, 2015 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |